Journal article
Effects of early intensive blood pressure-lowering treatment on the growth of hematoma and perihematomal edema in acute intracerebral hemorrhage: The intensive blood pressure reduction in acute cérébral haemorrhage trial (INTERACT)
CS Anderson, Y Huang, H Arima, E Heeley, C Skulina, MW Parsons, B Peng, Q Li, S Su, QL Tao, YC Li, JD Jiang, LW Tai, JL Zhang, E Xu, Y Cheng, LB Morgenstern, J Chalmers, JG Wang
Stroke | LIPPINCOTT WILLIAMS & WILKINS | Published : 2010
Abstract
Background and Purpose-The Intensive Blood Pressure Reduction In Acute cérébral Haemorrhage Trial (INTERACT) study suggests that early intensive blood pressure (BP) lowering can attenuate hematoma growth at 24 hours after intracerebral hemorrhage. The present analyses aimed to determine the effects of treatment on hematoma and perihematomal edema over 72 hours. Methods-INTERACT included 404 patients with CT-confirmed intracerebral hemorrhage, elevated systolic BP (150 to 220 mm Hg), and capacity to start BP-lowering treatment within 6 hours of intracerebral hemorrhage. Patients were randomly assigned to an intensive (target systolic BP 140 mmHg) or standard guideline-based management of BP (..
View full abstractGrants
Awarded by National Health and Medical Research Council (NHMRC) of Australia
Funding Acknowledgements
[ "The INTERACT study was supported by a Program Grant (358395) from the National Health and Medical Research Council (NHMRC) of Australia. The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.", "C. S. A. holds a Principal Research Fellowship (PRF) from the NHMRC. He receives consulting and lecture fees from Astra Zeneca, Boehringer Ingelheim, Novo Nordisk, Sanofi-Aventis, and Servier; L. B. M. receives consulting and lecture fees from Astra Zeneca, Boehringer Ingelheim, Novo Nordisk, and Sanofi-Aventis; J. C. receives lecture fees and research grants administered through the University of Sydney as Co-Principal Investigator for PROGRESS and ADVANCE from Servier; J. G. W. receives consulting and lecture fees from Astra-Zeneca, Novartis, Omron, Pfizer, and Servier." ]